Media OutReach
eefit Returns to the International Academic Stage — Patented Far Infrared Technology Praised by Nobel Laureate and Renowned Scientists
In the context of improving the lifestyle and functional regulation of middle-aged and elderly people, we seek to help improve their health in a gentle and sustainable manner by exploring new health protection paths outside of traditional medicine.
“The 9th Young Scholars Conference on Ion Channels and Receptors & Forum on Biophysics and Innovative Drug Discovery” was held in June 2025. As a leading energy healthcare technology company, “eefit” became the focus of the event, revealing to the world the innovative application of their patented far infrared technology in healthcare, with results verified by internationally renowned academics and authorities. The benefit provides systematic health management solutions for the middle-aged and elderly population through non-invasive and non-drug methods, creating a new chapter in health technology.
Recognized by Nobel Laureate and Renowned Scientists, eefit Far Infrared Technology is Acclaimed by International Authorities
Organized by the Macau University of Science and Technology (M.U.S.T.), this forum brought together experts in various disciplines from around the world, including neuroscientists and biophysicists. In attendance was 1991 Nobel Laureate in Physiology or Medicine Dr. Erwin Neher, who attended the event as the keynote speaker. It’s worth noting that eefit has been collaborating closely with “Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery” since 2021, promoting transformative scientific research in far infrared technology.
On a similar note, Prof. Vincent Wong of M.U.S.T. (among the top 2% of scientists in the world) introduced the significant effects of eefit’s patented far infrared technology in improving intestinal microecology, regulating cell immunity, and alleviating symptoms of rheumatoid arthritis. His team’s latest research has confirmed that this technology not only can enhance cerebral blood flow and reduce brain damage in patients with ischemic stroke but can also provide an innovative solution for rehabilitation treatment.
Far Infrared Technology is Changing Our Lives
eefit Has Constructed an All-encompassing “Prevention + Maintenance + Restoration” Health Management System
The middle-aged and elderly population is plagued by health issues, such as chronic pain, sleep disorders, immune system disorders, and Alzheimer’s disease. eefit provides comprehensive solutions to address these issues through developing innovative healthcare products. At the forum, experts gathered at the booth set up by eefit to experience firsthand how technology redefines the health management of the elderly.
Case 1: Disease prevention – protecting brain health at the source
eefit’s patented technology reduces the risk of Alzheimer’s disease by reducing Aβ deposits and abnormal tau proteins. The latest research paper presented on-site showed that eefit far infrared energy can penetrate the blood-brain barrier, intervene in pathological protein aggregation, and build a strong line of defense for brain health.
Case 2: Brain healthcare – improving stroke sequelae and neurological function
For patients suffering from sequelae of stroke, eefit Luminous Energy Helmet and Meridian Pro Illuminator can promote microcirculation in the head and improve cerebral blood flow. The research conducted by the research team of Prof. Vincent Wong has confirmed that this technology can reduce stroke sequelae symptoms and dizziness. An expert user at the forum excitedly shared his feedback, “I am a loyal fan of eefit products. I wear the Luminous Energy Helmet for 20 minutes daily. After one month, I find my memory improved, and I don’t get dizzy as often.”
Case 3: Chronic pain management – quick relief for joint and muscle pain
In the field of pain management, products like EEFit Lite can accurately irradiate pain points and inhibit the release of inflammatory factors. Experts verified that “10 minutes of irradiation can reduce knee pain on a pain scale from 6 to 3, with effects lasting for more than 2 hours”.
Case 4: Sleep quality – natural relief for nervous system
eefit far infrared technology can relieve insomnia by regulating nervous system functions. eefit data shows that after daily use for 2 weeks, over 80% of users experienced a 50% reduction in the time they took to fall asleep, as well as an increased duration of deep sleep.
Case 5: Digestive system repair – two-way regulation of intestinal microecology
eefit far infrared energy achieves two-way regulation of gut microbiota in an innovative manner by inhibiting the excessive proliferation of pathogens while promoting the growth of beneficial bacteria and regulating the imbalance of intestinal microecology. Experimental data shows that after two weeks of intervention, the alpha diversity of gut microbiota (Chao1 index) increased by 30%, and abdominal bloating decreased by 45%.
Nobel Laureate Dr. Neher and Prof. Vincent Wong expressed that the eefit technology system demonstrates innovation and practicality at the international forefront, establishing a new model for the health management of the elderly.
Integrating Industry, Academia and Research: Innovative Paths Leading Industry Development
eefit first introduced far infrared technology into health management through independent technology R&D and commercialization execution, which then attracted collaboration with reputable scientific research institutions. This closed-loop ecosystem of “Demand-Driven Innovation” demonstrates benefit’s ability to focus on the core benefits of products by starting from users’ pain points then feeding back technological improvements into scientific research.
At the forum banquet, eefit’s Founder and Chairman Prof. Nick Wang remarked, “We are honoured, looking back on our eight-year partnership between eefit and the research laboratory. This period of collaboration with deep integration of industry, academia and research has not only pioneered groundbreaking research but also produced fruitful scientific and technological achievements.” He emphasized that eefit has always been “user demand-oriented” at its core, by first verifying the value of technology through market research and then extending the application boundaries with the help of prominent scientific researchers to achieve a seamless connection “from lab to real life”.
The Future is Here: eefit’s Multi-dimensional Layout is Leading a New Era of Far Infrared Healthcare Technology
eefit’s future development focuses on three strategic directions: In terms of scaling technological capabilities, they will continue to increase their investment on R&D and explore new boundaries of far infrared technology applications in more areas that impact human health; In terms of advancing global collaboration, they will strengthen partnerships with notable international scientific research institutions and accelerate the process of global adoption; In the field of inclusive health accessibility, they will popularize home healthcare solutions through verified consumer-level healthcare products such as EEFit Lite, Chi Vitaliser, and Luminous Energy Helmet; and they will continue to pioneer the extension of far infrared technology in the field of health supplements, building an all-encompassing health management system of “External healthcare devices + Internal balancing nutrition”.
As a leading energy healthcare technology company in Hong Kong, eefit’s all-encompassing health management system has been universally recognized by respected international scientists. Leveraging their pioneering edge in commercialisation and the ability to transform based on scientific research, eefit will continue to spearhead global innovation of far infrared healthcare technology, ensuring the benefits of science-backed wellness reach everyone.
Hashtag: #eefit
https://www.eefit.com/
https://www.facebook.com/eefit
The issuer is solely responsible for the content of this announcement.
About “The 9th Young Scholars Conference on Ion Channels and Receptors & Forum on Biophysics and Innovative Drug Discovery”
This forum was jointly organized by the Branch of Ion Channels & Receptors, Chinese Neuroscience Society, and Macau University of Science and Technology (M.U.S.T.). It is an important academic event in China focusing on the field of ion channels and receptors. This forum has been held for eight consecutive years and is an important platform for promoting cutting-edge research, innovative drug development and cooperation, and international academic exchanges.
Media OutReach
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia
Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.
The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.
“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem
2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.
Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.
D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.
In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.
By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.
The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.
Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.
For investor and media enquiries
Please email to **@****an.com
Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech
The issuer is solely responsible for the content of this announcement.
Ingdan, Inc.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
Media OutReach
Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events
- European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
- With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.
Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.
Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.
Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD
Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.
The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.
Changan Standard: Proven in the Alps, Bound for the World
Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.
Hashtag: #Changan
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn